Učitavanje...
Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
BACKGROUND: Over half of patients treated with antibodies blocking programmed death-1 receptor (anti-PD-1) for melanoma experience disease progression. We aimed to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed on anti-PD-1 therapy. METHODS: We evaluate...
Spremljeno u:
| Izdano u: | Cancer |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7695037/ https://ncbi.nlm.nih.gov/pubmed/32463489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32984 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|